Literature DB >> 23604999

Potential gonadotoxicity of treatment in relation to quality of life and mental well-being of male survivors of childhood acute lymphoblastic leukemia.

Mirja Erika Gunn1, Päivi Maria Lähteenmäki, Leena-Riitta Puukko-Viertomies, Markus Henriksson, Risto Heikkinen, Kirsi Jahnukainen.   

Abstract

PURPOSE: Results of earlier studies concerning quality of life (QOL) and psychosocial coping of childhood acute lymphoblastic leukemia (ALL) survivors have been inconsistent. Some treatments for ALL affect testicular function and we hypothesized that this may influence the QOL and psychosocial coping of male survivors. Our aims were to assess the QOL and psychosocial coping of male long-term ALL survivors and to evaluate the effect of both testosterone level and the potential gonadotoxicity of various treatment modalities on them.
METHODS: Fifty-two male long-term survivors treated for childhood ALL at Helsinki University Hospital between 1970 and 1995, and 56 age- and gender-matched controls were studied. The participants completed a self-report questionnaire including questions on sociodemographics, RAND-36 to assess QOL, General Health Questionnaire and Beck Depression Inventory to assess mental well-being, and CAGE to assess alcohol abuse/dependence. Testosterone levels were measured, and treatment details were reviewed.
RESULTS: ALL survivors in general had QOL close to that of controls or population norms. Decreased QOL was seen in physical health-related subscales, and vitality and emotional well-being were lowered in survivors with more gonadotoxic treatment modalities. No single independent factor in the treatment or the level of testosterone could, however, be found to clearly explain the variation in QOL scores of the survivors. Mental well-being of most of the survivors was good, but a subgroup with previous cyclophosphamide treatment or testicular irradiation showed increased risk of psychiatric morbidity.
CONCLUSIONS: The male ALL survivors generally cope well, but increased focus on specific risk groups seems to be necessary. Further studies using patient interviews would probably point out issues concerning the QOL and psychosocial coping of ALL survivors, which may not emerge in these screening studies. IMPLICATIONS FOR CANCER SURVIVORS: In general, more attention should be paid for physical functioning of childhood ALL survivors. Increased focus should also be on QOL and mental well-being of survivors with more gonadotoxic treatment modalities and those whose diagnosis was made in their adolescence.

Entities:  

Mesh:

Year:  2013        PMID: 23604999     DOI: 10.1007/s11764-013-0285-7

Source DB:  PubMed          Journal:  J Cancer Surviv        ISSN: 1932-2259            Impact factor:   4.442


  23 in total

1.  Extent of alcohol consumption among adult survivors of childhood cancer: the British Childhood Cancer Survivor Study.

Authors:  Clare Frobisher; Emma R Lancashire; Raoul C Reulen; David L Winter; Michael C G Stevens; Michael M Hawkins
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-05       Impact factor: 4.254

2.  High health-related quality of life among long-term survivors of childhood acute lymphoblastic leukemia.

Authors:  Marika J Harila; Jarmo Salo; Marjatta Lanning; Ilpo Vilkkumaa; Arja H Harila-Saari
Journal:  Pediatr Blood Cancer       Date:  2010-08       Impact factor: 3.167

3.  Educational achievement, employment and living situation in long-term young adult survivors of childhood cancer in the Netherlands.

Authors:  N E Langeveld; M C Ubbink; B F Last; M A Grootenhuis; P A Voûte; R J De Haan
Journal:  Psychooncology       Date:  2003 Apr-May       Impact factor: 3.894

4.  Semen quality and fertility in adult long-term survivors of childhood acute lymphoblastic leukemia.

Authors:  Kirsi Jahnukainen; Risto Heikkinen; Markus Henriksson; Trevor G Cooper; Leena-Riitta Puukko-Viertomies; Outi Mäkitie
Journal:  Fertil Steril       Date:  2011-08-24       Impact factor: 7.329

5.  Detecting alcoholism. The CAGE questionnaire.

Authors:  J A Ewing
Journal:  JAMA       Date:  1984-10-12       Impact factor: 56.272

6.  Long-term survivors of childhood cancer report quality of life and health status in parity with a comparison group.

Authors:  Kay K Sundberg; Eva Doukkali; Claudia Lampic; Lars E Eriksson; Johan Arvidson; Lena Wettergren
Journal:  Pediatr Blood Cancer       Date:  2010-08       Impact factor: 3.167

7.  Low depressive symptom and mental distress scores in adult long-term survivors of childhood acute lymphoblastic leukemia.

Authors:  Marika J Harila; Tomi I T Niinivirta; Satu Winqvist; Arja H Harila-Saari
Journal:  J Pediatr Hematol Oncol       Date:  2011-04       Impact factor: 1.289

8.  Scholastic achievements of childhood leukemia patients: a nationwide, register-based study.

Authors:  Arja H Harila-Saari; Päivi M Lähteenmäki; Eero Pukkala; Pentti Kyyrönen; Marjatta Lanning; Risto Sankila
Journal:  J Clin Oncol       Date:  2007-08-10       Impact factor: 44.544

9.  Psychosocial outcomes and health-related quality of life in adult childhood cancer survivors: a report from the childhood cancer survivor study.

Authors:  Lonnie K Zeltzer; Qian Lu; Wendy Leisenring; Jennie C I Tsao; Christopher Recklitis; Gregory Armstrong; Ann C Mertens; Leslie L Robison; Kirsten K Ness
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-02       Impact factor: 4.254

10.  Psychological outcomes in long-term survivors of childhood leukemia, Hodgkin's disease, and non-Hodgkin's lymphoma: a report from the Childhood Cancer Survivor Study.

Authors:  Brad J Zebrack; Lonnie K Zeltzer; John Whitton; Ann C Mertens; Lorrie Odom; Roger Berkow; Leslie L Robison
Journal:  Pediatrics       Date:  2002-07       Impact factor: 9.703

View more
  5 in total

1.  Leydig Cell Function in Male Survivors of Childhood Cancer: A Report From the St Jude Lifetime Cohort Study.

Authors:  Wassim Chemaitilly; Qi Liu; Laura van Iersel; Kirsten K Ness; Zhenghong Li; Carmen L Wilson; Tara M Brinkman; James L Klosky; Nicole Barnes; Karen L Clark; Rebecca M Howell; Susan A Smith; Matthew J Krasin; Monika L Metzger; Gregory T Armstrong; Michael W Bishop; Hanneke M van Santen; Ching-Hon Pui; Deo Kumar Srivastava; Yutaka Yasui; Melissa M Hudson; Leslie L Robison; Daniel M Green; Charles A Sklar
Journal:  J Clin Oncol       Date:  2019-09-26       Impact factor: 44.544

2.  Isolated late testicular relapse of B-cell acute lymphoblastic leukemia treated with intensive systemic chemotherapy and response-based testicular radiation: A Children's Oncology Group study.

Authors:  Julio C Barredo; Caroline Hastings; Xiamin Lu; Meenakshi Devidas; Yichen Chen; Daniel Armstrong; Naomi Winick; Brent Lee Wood; Rochelle Yanofsky; Mignon Loh; Julie M Gastier-Foster; Dean Thomas Jorstad; Robert Marcus; Kim Ritchey; William L Carrol; Stephen P Hunger
Journal:  Pediatr Blood Cancer       Date:  2017-12-29       Impact factor: 3.167

Review 3.  Social adjustment across the lifespan in survivors of pediatric acute lymphoblastic leukemia (ALL): a systematic review.

Authors:  Sara Cho; Courtney Tromburg; Caitlin Forbes; Andrew Tran; Elleine Allapitan; Taryn Fay-McClymont; Kathleen Reynolds; Fiona Schulte
Journal:  J Cancer Surviv       Date:  2022-01-06       Impact factor: 4.442

4.  Health-related quality of life of survivors of childhood acute lymphoblastic leukemia: a systematic review.

Authors:  J Vetsch; C E Wakefield; E G Robertson; T N Trahair; M K Mateos; M Grootenhuis; G M Marshall; R J Cohn; J E Fardell
Journal:  Qual Life Res       Date:  2018-01-25       Impact factor: 4.147

5.  Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study.

Authors:  Sarah L Kerns; Chunkit Fung; Patrick O Monahan; Shirin Ardeshir-Rouhani-Fard; Mohammad I Abu Zaid; AnnaLynn M Williams; Timothy E Stump; Howard D Sesso; Darren R Feldman; Robert J Hamilton; David J Vaughn; Clair Beard; Robert A Huddart; Jeri Kim; Christian Kollmannsberger; Deepak M Sahasrabudhe; Ryan Cook; Sophie D Fossa; Lawrence H Einhorn; Lois B Travis
Journal:  J Clin Oncol       Date:  2018-04-04       Impact factor: 44.544

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.